The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Salinosporamide Natural Products: Potent 20 S Proteasome Inhibitors as Promising Cancer Chemotherapeutics
Open accessAbstract
Proteasome inhibitors are rapidly evolving as potent treatment options in cancer therapy. One of the most promising drug candidates of this type is salinosporamide A from the bacterium Salinispora tropica. This marine natural product possesses a complex, densely functionalized γ‐lactam‐β‐lactone pharmacophore, which is responsible for its irreversible binding to its target, the β subunit of the 20S proteasome. Salinosporamide A entered phase I clinical trials for the treatment of multiple myeloma only three years after its discovery. The strong biological activity and the challenging structure of this compound have fueled intense academic and industrial research in recent years, which has led to the development of more than ten syntheses, the elucidation of its biosynthetic pathway, and the generation of promising structure–activity relationships and oncological data. Salinosporamide A thus serves as an intriguing example of the successful interplay of modern drug discovery and biomedical research, medicinal chemistry and pharmacology, natural product synthesis and analysis, as well as biosynthesis and bioengineering.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Protein degradation and protection against misfolded or damaged proteins.
Goldberg, A. L. (2003) · Nature · doi:10.1038/nature02263 · Cited by 2,088
Fenteany, G., Standaert, R. F., Lane, W. S., Choi, S., Corey, E. J., & Schreiber, S. L. (1995) · Science · doi:10.1126/science.7732382 · Cited by 1,583
Chauhan, D., Catley, L., Li, G., Podar, K., Hideshima, T., Velankar, M., Mitsiades, C., Mitsiades, N., Yasui, H., Letai, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.013 · Cited by 694
Groll, M., Kim, K. B., Kairies, N., Huber, R., & Crews, C. M. (2000) · Journal of the American Chemical Society · doi:10.1021/ja993588m · Cited by 304
Discovery and development of the anticancer agent salinosporamide A (NPI-0052)
Fenical, W., Jensen, P. R., Palladino, M. A., Lam, K. S., Lloyd, G. K., & Potts, B. C. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.10.075 · Cited by 291
Newman, D. J., & Cragg, G. M. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043364982 · Cited by 161
Cited by
Antibiotics: past, present and future
Hutchings, M. I., Truman, A. W., & Wilkinson, B. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.10.008 · Cited by 2,370
Gerwick, W. H., & Moore, B. S. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.014 · Cited by 601
Self-citationEnzymatic Halogenation and Dehalogenation Reactions: Pervasive and Mechanistically Diverse
Agarwal, V., Miles, Z. D., Winter, J. M., Eustáquio, A. S., El Gamal, A. A., & Moore, B. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00571 · Cited by 439
Self-citationBiologically active γ-lactams: synthesis and natural sources
Caruano, J., Muccioli, G. G., & Robiette, R. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob01349j · Cited by 436
Tang, X., Li, J., Millán-Aguiñaga, N., Zhang, J. J., O’Neill, E. C., Ugalde, J. A., Jensen, P. R., Mantovani, S. M., & Moore, B. S. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00658 · Cited by 253
Self-citation
Metadata
- Authors
- Gulder, T. A. M., & Moore, B. S.
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2010-10-06
- Volume
- 49
- Issue
- 49
- Pages
- 9346-9367
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2168285676
- Cited by
- 246
- References
- 8
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.